Previous Article | Next Article ![]()
Clinical and Diagnostic Laboratory Immunology, November 2001, p. 1279-1281, Vol. 8, No. 6
Albany Medical College, Albany, New
York,1 and GlaxoSmithKline, Research
Triangle Park, North Carolina2
Received 25 May 2001/Returned for modification 5 June 2001/Accepted 20 August 2001
The average 50% inhibitory concentration (IC50) values
for AD169 were 0.22 ± 0.09 µM 1263W94 and 5.36 ± 0.12 µM ganciclovir. For 35 human cytomegalovirus (HCMV) clinical isolates
the average IC50 was 0.42 ± 0.09 µM 1263W94, and
for 26 ganciclovir-susceptible HCMV clinical isolates the average
IC50 was 3.78 ± 1.62 µM ganciclovir. Nine HCMV
clinical isolates that were resistant to ganciclovir were completely
susceptible to 1263W94.
1071-412X/01/$04.00+0 DOI: 10.1128/CDLI.8.6.1279-1281.2001
Copyright © 2001, American Society for Microbiology. All rights reserved.
Inhibition of Ganciclovir-Susceptible and
-Resistant Human Cytomegalovirus Clinical Isolates by the
Benzimidazole L-Riboside 1263W94
*
Corresponding author. Mailing address: Center for
Immunology and Microbial Disease, Albany Medical College, Mail Code
151, 47 New Scotland Ave., Albany, NY 12208. Phone: (518) 262-5174. Fax: (518) 262-5748. E-mail: mcsharj{at}mail.amc.edu.
This article has been cited by other articles:
| Antimicrob. Agents Chemother. | Clin. Microbiol. Rev. | Infect. Immun. |
|---|---|---|
| J. Clin. Microbiol. | J. Virol. | ALL ASM JOURNALS |